Patrys Limited (ASX:PAB) has been granted a U.S. patent for its anti-cancer candidate PAT-LM1 for use in treating colon cancer metastasis.
Based in Melbourne, Patrys is focused on the development of antibodies as therapies for a range of different cancers.
Patrys has already secured eight patents across the PAT-LM1 families in three jurisdictions - the U.S., Europe and UK.
PAT-LM1 is a natural human antibody that has shown great promise in laboratory and animal testing as a potential treatment for multiple types of cancer like colon, lung, breast, ovary and pancreas.
The antibody attacks a protein called NONO which is expressed in 98% of over 200 different types of cancer cells screened.
NONO has been shown to play a role in modulating cell death and repair mechanisms and as a marker in estrogen receptor negative breast cancer tumours.
Patrys has two technology platforms, IgM monoclonal antibodies and a suite of nuclear penetrating antibodies for cancer therapy.
In March 2016, Patrys had licensed the exclusive rights to two nuclear-penetrating lupus antibodies for cancer therapy from Yale University.